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Abstract 
Background: Drug resistance in Plasmodium falciparum has posed an obstacle to effective treatment and challenges 
many malaria control programmes in endemic areas. In Angola, until 2003, chloroquine (CQ) was used as first-line 
therapy for uncomplicated malaria. It was replaced initially by amodiaquine and, in 2006, by artemisinin-based com-
bination therapy (ACT) with artemether-lumefantrine (AL, Coartem®). Efficacy study of ACT, conducted in Angola 
between 2004 and 2005, showed a baseline efficacy of ≈99 %.
Methods: 103 malaria patients were enrolled according to WHO proceedings. Patients were followed up with clini-
cal and parasitological evaluations for 28 days, parasite density and identification was evaluated by microscopy, the 
pfmsp2 were genotyped by nested-PCR, to distinguish parasite recrudescence from new infections; the polymor-
phisms at codons 86 and 1246 of pfmdr1 gene, and 769 of pfatp6 gene were assessed by PCR–RFLP and sequencing 
for pfk13-propeller genotype.
Results: The cure rate was 91.3 %. The obtained results showed that from 103 patients, 12.6 % (n = 13) still had para-
sitaemia 1 day after the treatment was finished. On day 0, of the 94 evaluated samples, wild-type alleles were identi-
fied in 73.4 % (n = 69) for pfmdr1 N86Y position and only one sample carried the mutant allele (Y) for pfmdr1 1246; 
14 % of these samples showed increased pfmdr1 copy number; 100 % (n = 21) had wild-type allele of k13 gene in all 
the studied positions.
Discussion: These results showed changes in parasite profile susceptibility to AL in comparison to the baseline data 
from 2002 to 2004 and on the genotyping characteristics; the clinical outcome after treatment with AL did not link 
a particular genotype with treatment failure; observed changes do not provide sufficient evidence for a treatment 
policy change, but they suggest that a carefully monitoring is needed in this area.
Keywords: Plasmodium falciparum, Artemether-lumefantrine, Therapeutic efficacy, Polymorphisms, pfmdr1, pfatp6, 
pfK13, Angola
© 2015 Kiaco et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Malaria Journal
*Correspondence:  kinanga.kiaco@ihmt.unl.pt 
3 Serviços de Saúde das Forças Armadas Angolanas, Estado Maior General 
das Forças Armadas, Luanda, Angola
Full list of author information is available at the end of the article
Page 2 of 10Kiaco et al. Malar J  (2015) 14:504 
Background
Malaria is the leading cause of morbidity in countries 
where it is endemic; an estimated 3.3 billion people are 
at risk of being infected with malaria and developing dis-
ease worldwide [1, 2] though, at present, some malaria 
control programmes are being successful [3]. Malaria 
control programmes currently comprise integrated inter-
ventions, including vector control with use of mosquito 
nets and spraying with insecticides, intermittent preven-
tive treatment in pregnancy (IPT), early diagnosis and 
effective treatment of clinical cases [4]. The reports of 
World Health Organization (WHO) refer that malaria 
mortality rate declined by 47 % between 2000 and 2013 
globally and 54  % in the WHO African region due to 
malaria control interventions [2].
Malaria remains a public health challenge in Angola 
with changes in mortality over the last 3 years. According 
to an unpublished report (2014) of National Malaria Con-
trol Programme (NMCP), between 2010 and 2012 deaths 
attributed to malaria decreased from 8114 to 5736, but 
in 2013, 1,999,868 cases and 7300 deaths due to malaria 
were reported [2]. In this endemic country, malaria infec-
tion is still the major cause of morbidity and mortality, 
accounting for 25 % of health care demands, 20 % of hos-
pitalization requirements, 40 % of perinatal death, 25 % 
of maternal death and is the main reason of absenteeism, 
both at work and in schools [5].
An evaluation of anti-malarial efficacy of chloroquine 
(CQ), amodiaquine (AQ) and sulfadoxine-pyrimeth-
amine (SP) carried out by the Angolan NMCP, in the 
period between 2000 and 2005, revealed treatment 
failure of 57.7, 3.8 and 15.4  %, respectively. Studies of 
artemether-lumefantrine (AL) and artesunate +  amodi-
aquine (ASAQ), efficacy, conducted in 2004 and 2005, 
revealed efficacy of ≈99 % [6, 7]. Based on these results 
and on WHO recommendations, ACT was adopted for 
uncomplicated malaria treatment in 2006, with AL as the 
first-line drug combination [8, 9].
Despite the WHO recommendation of ACT, there are 
worrying signs associated with loss of efficacy. Existence 
of isolates from different areas with markedly reduced 
susceptibility to ACT was reported. A loss of efficacy of 
ACT in western Cambodia, with slower parasitological 
responses to anti-malarial drugs, principally an unusually 
high failure rate of artesunate + mefloquine, suggesting 
the emergence of artemisinin resistance, were published 
in 2009. In addition, prolongation of parasite clearance 
time (PCT) has been reported on the Thai-Myanmar 
border, indicating that artemisinin resistance could be 
spreading outside Cambodia [4, 10, 11].
The genetic basis of artemisinin resistance is not yet 
known; several polymorphism as Plasmodium falcipa-
rum multidrug resistant 1 (pfmdr1) gene copy number, 
or specific point mutations in its codons 86, 184, 1034, 
1042 and 1246 have been associated with the suscep-
tibility to this class of anti-malarials [4, 12]. Certain 
molecular markers have been linked with resistance 
to lumefantrine, namely the pfmdr1 copy number and 
the pfmdr186N allele [13, 14]. Multiple copies of the 
pfmdr1 gene has been linked with lumefantrine and 
mefloquine resistance and to the risks of treatment fail-
ure with artesunate–mefloquine and AL in Southeast 
Asia, while mutations at the codon 86 of the pfmdr1 
gene can modulate lumefantrine efficacy [14, 15]. Poly-
morphisms in the gene pfatp6 can also mediate changes 
in artemisinin susceptibility; specially the mutation 
S769N [13, 16, 17]. According to the WHO, a molecu-
lar marker of artemisinin resistance was recently iden-
tified, in studies in Cambodia where specific mutations 
in the Kelch 13 (k13) propeller domain were found to 
be associated with delayed parasite clearance; this may 
open new possibilities for tracking resistance to arte-
misinins [18–20].
The present study aims to evaluate the therapeutic effi-
cacy of Coartem® for the treatment of uncomplicated P. 
falciparum infection, in Luanda, Angola, and to analyse 
the polymorphisms in pfmdr1, pfatp6, and K13 genes 
previously associated to susceptibility to AL, 6 years after 
its introduction on this area.
Methods
This was an interventional prospective single cohort 
study conducted in Luanda, Angola, considered as 
malaria mesoendemic stable area. Blood sample collec-
tion was carried out in 2011, 2012 and 2013 in the period 
of high malaria transmission (between April and June). 
Patients were recruited and followed at three health cen-
tres: a Catholic Church health care unit (Hospital Divina 
Providência) and two military health units (Clínica do 
Exército and Instituto Superior Técnico Militar). Subjects 
were selected among children and adults with confirmed 
malaria infection, based on the WHO 2009 guidelines for 
drug efficacy study [21].
Patients were eligible to participate, if older than 
6 months of age, axillary temperature of at least 37.5 °C or 
history of fever within the last 24 h, with symptoms com-
patible with malaria, and infection with P. falciparum 
confirmed by microscopy. Further, other criteria were 
included: (a) to have non-complicated malaria (according 
to a medical evaluation and according to asexual para-
sitaemia); (b) to have an initial parasite density between 
1000 and 100,000 asexual parasites/μL; (c) exclusion of 
the concomitant diseases, after a clinical interview and 
examination; (d) voluntary participation in the study with 
written informed consent; (e) commitment to attend the 
follow-up examination on indicated days.
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Patients with evidence of severe malaria or any other 
disease, presence of severe malnutrition or with appear-
ance or history of adverse effects due to any anti-malar-
ial drug, to other medicines, or to other causes were 
excluded from the study. Patients who did not meet these 
basic enrolment criteria were treated in accordance with 
routine practice of each institution. Patient’s selection 
was conducted by a skilled team, including physicians, 
nurses, microscopy’s technicians and one epidemiologist.
Ethical approval was obtained from the Ethic Commit-
tee of National Public Health Institute (Angolan Ministry 
of Health). All participants received information about 
study objectives and protocols and informed written con-
sent was obtained from all eligible participants/parents 
or guardians.
Sample size should be calculated based on the expected 
proportion of treatment failures in the studied popula-
tion [21]. As this information was not available for this 
area, a clinical failure rate of 50 % (P = 0.5) was assumed. 
A confidence level of 95  % and precision of 10  % were 
considered. In this study, a minimum of 96 included 
patients are required [21].
Clinical analyses
Patients were treated with six doses of AL (20  mg 
artemether and 120 mg lumefantrine tablets; Coartem®, 
Novartis, Basel Switzerland). For adults, four tablets were 
administered twice a day; doses were adjusted according 
to weight for children under 35 kg [8]. At Hospital Divina 
Providência, children up to 12 years old stayed for direct 
observation (DOT) at the clinic, for the 3 days of medica-
tion. For patients from the remaining clinics, Coartem® 
was given to the patient to be taken at home. Patients 
were recommended to take the tablets with fatty food or 
milk to improve their absorption [8].
Clinical assessment was performed on recruitment 
(day 0) and on each follow-up day (days 1, 2, 3, 7, 14, 21 
and 28). Thick blood films stained with Giemsa were pre-
pared and examined [22], on each day and capillary blood 
sample was collected on filter paper for DNA analysis 
[23, 24]. The molecular analysis was performed at Insti-
tuto de Higiene e Medicina Tropical (IHMT), in Portugal.
Outcomes were classified according to WHO anti-
malarials drug efficacy test guidelines 2009 [21] as: 
‘Early Treatment Failure’ (ETF) in which there are dan-
ger signs or failure to reduce parasitaemia levels by day 
3; Late Treatment Failure (LTF), which consists of two 
subcategories: ‘Late Clinical Failure’ (LCF) in which 
there are danger signs or parasitaemia and fever occur-
ring between days 4 and 28, and ‘Late Parasitological 
Failure’ (LPF) in which there is parasitaemia without 
fever between days 4 and 28; ‘Adequate clinical and 
parasitological response’ (ACPR) is the absence of 
parasitaemia on day 28, irrespective of axillary tempera-
ture, in patients who did not previously meet any crite-
ria of treatment failure [21]. Patients meeting criteria of 
treatment failure ended the study and were treated with 
intravenous quinine. Signs, symptoms and any adverse 
events that developed after drug intake were observed 
and reported during clinical examination at the follow 
up days.
Molecular analysis
Extraction of DNA from dried blood spot on filter paper 
was carried out using phenol–chloroform method pre-
viously tested [25, 26]. Plasmodium falciparum nested-
PCR was performed according to the protocol described 
by Snounou et  al. [27, 28], for identification of Plas-
modium species and for merozoite surface protein2 
(pfmsp2—FC and IC families) genotyping of on D0 and to 
positive samples from post-treatment (after D7) in order 
to distinguish parasite recrudescence from reinfection 
[29, 30]. Recrudescence was defined as the presence of at 
least one matching parasite population from day 0, while 
reinfections were defined as the absence of any matching 
parasite population from D0.
pfmdr1 and pfatp6 genotyping
The analysis of polymorphisms of the parasite, based on 
mutations at positions 86 and 1246 of pfmdr1, and 749 
of pfatp6 genes were performed by conventional RFLP-
PCR [31]. ApoI (New England Biolabs) was used to iden-
tify pfmdr1 86N, EcoRV (New England Biolabs) assessed 
to the 1246Y alleles and enzyme RsaI (New England 
Biolabs) for pfatp6 769S allele [31, 32]. Restriction frag-
ments were analysed by electrophoresis using 2  % aga-
rose (SeaKem® LEAgarose, ref. 50004) gel stained with 
ethidium bromide (Sigma-Aldrich E1510) and visualized 
under UV [27, 33].
The variation of pfmdr1 gene copy number was evalu-
ated using real-time PCR (iCycle IQ™ (BIO-RAD), as 
previously described [15, 33, 34]. Briefly, real-time PCR 
amplification was performed under the following condi-
tions: 10 min of pre-incubation at 95  °C followed by 40 
cycles for 15  s at 95  °C and 1  min at 60  °C. PCR reac-
tions were carried out in 20 µL final volume in a 96-well 
plate (Bioplastics, ref. B50501), with 7.5 µL of iQ™ SYBR® 
Green Supermix (BIO-RAD, ref. 170-8880), 300  nM 
primers and 2 µL de DNA was added to the mixture. All 
samples were run in triplicate and the DNA of P. falcipa-
rum strains, 3D7 and Dd2 were used as single and mul-
tiple copy calibrators, respectively. pfmdr1 copy number 
was calculated using a comparative threshold method 
(2−ΔΔCt method) [34]. For this study, it was considered 
increased pfmdr1 copy number when the sample had 
pfmdr1 folds >1.5 by RT-PCR.
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Sequencing the K13‑propeller domain
The K13-propeller domain was amplified according to 
previously described methods [20], for identification of 
the polymorphisms of codons G449A, N458Y, T474I, 
A481V, Y493H, T508  N, G533S, N537I, R539T, I543T, 
P553L, R561H, V568G, P574L, C580Y and D584V. Dou-
ble-strand sequencing of PCR products was performed 
by Stabvida Genomics LAB in Lisbon. Sequences were 
analysed with Multalin software to identify specific SNP 
combinations [19, 20].
Statistical analysis
Data were entered and analysed using Epi-info 7 version. 
Mixed infections thus contribute to the prevalence of 
both alleles were excluded of all statistical analyses.
Results and discussion
Sample selection
During the 3 years of study, a total of 3628 patients (adult 
and children) were screened for malaria parasites in the 
selected health care units. Of these, 972 (26.8 %) had pos-
itive microscopic malaria diagnosis; this result shows the 
need to consider the diverse causes of febrile syndrome 
in malaria endemic regions. Initially, 122 patients were 
selected and from these, nineteen were excluded: two 
vomited persistently, nine were lost during the follow-
up period and 8 had a negative PCR at day 0. A total of 
103 patients met the required criteria and were enrolled 
in the study; and from these 21 (20.4  %) were children 
under 5 years of age.
Treatment was well tolerated, no patients presented 
relevant complaints or treatment adverse effects.
Patients follow‑up
In this the study, in 2011, 37 patients were enrolled, 
33 in 2012 and 33 in 2013, giving a total sample of 103 
patients, aged between 6 months to 56 years of age; 716 
blood samples were collected during the follow up days 
for molecular analysis. The group of children under 
5 years of age represented 16 % of sampling (114 samples 
from 21 children). Distribution of observed patients and 
microscopy evaluation by days of follow-up is shown on 
Table 1.
Identification of Plasmodium falciparum species
On D3 (one day after finishing the Coartem® treatment), 
13 of the 103 patients (12.6  %) had parasites detectable 
by microscopy, six of those patients (5.8  % of the total) 
still had parasites detectable by microscopy on D7. Using 
the PCR method, 48 patients (46.6  %) on D3 and 35 
(34 %) on D7 gave positive results for presence of P. fal-
ciparum. Samples with positive PCR had correspondence 
with follow-up days with positive microscopic results 
for asexual forms and/or gametocytes. The high sensi-
tivity of the PCR method to detect the parasites at sub-
microscopic densities, gametocytes presence and errors 
in microscopic diagnostic are factors that can generally 
explain the difference on results obtained by microscopic 
and PCR methods [21, 22]. To minimize the microscopy 
error in this study, skilled technicians were involved. All 
Table 1 Distributions of the results by follow-up days (n = 103)
PCR, polymerase chain reaction; n, number of patients; (), relative frequency; (+), positive result; D, day of follow-up
Days of follow‑up D0 D1 D2 D3 D7 D14 D21 D28
2011
 Patients observed (n) 37 37 37 36 36 35 35 35
 Microscopy (+) 37 (100) 25 (67.5) 8 (21.6) 4 (11) 1 (2.8) 0 0 1 (2.8)
 PCR (+) 37 34 (92) 20 (54) 13 (36) 8 (22) 4 (11) 1 (2.8) 1 (2.8)
2012
 Patients observed (n) 33 (100) 33 33 33 33 32 31 31
 Microscopy (+) 33 27 (82) 6 (18) 4 (12) 2 (6) 1 (3) 0 0
 PCR (+) 33 30 (91) 19 (58) 14 (42) 10 (30) 1 (3) 0 0
2013
 Patients observed (n) 33 33 33 33 33 29 29 29
 Microscopy (+) 33 (100) 30 (91) 6 (18) 5 (15) 3 (9) 0 0 1 (3.4)
 PCR (+) 33 33 (100) 30 (91) 21 (63.6) 17 (51.5) 11 (38) 5 (17) 3 (10)
Total
 Patients observed (n) 103 103 103 102 102 96 95 95
 Microscopy (+) 103 (100) 82 (80) 20 (19) 13 (13) 6 (6) 1 (1) 0 2 (2)
 PCR (+) 103 97 (94) 69 (67) 48 (47) 35 (34) 16 (17) 6 (6) 4 (4)
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individuals that treatment responses were identified as 
treatment failures were both microscopic and PCR posi-
tive at respective days.
According to the years of inclusion, it was observed 
that the proportion of samples with parasites detectable 
by PCR at day 3 and 7 increased progressively from 2011 
to 2013 as showed on Table 1.
Gametocyte carriage
Gametocytes were detected in 15.5  % (n  =  16) of the 
patients on D0. Seven patients (6.8  %) still had game-
tocytes detectable on D7 and were still found in three 
patients on D14, in one on D21 and one on D28, after 
the asexual parasites had been cleared. The presence of 
gametocytes on D0 can suggest the usual existence in the 
endemic areas of long-lasting infections, initially asymp-
tomatic with low parasitaemia, which can turn manifest 
when there is debility of host defense or new additional 
infection. This condition promotes maintenance of dis-
ease transmission in the community [35].
Fever clearance
The average fever clearance time was ≈24 h after the ini-
tial dose of treatment, 97 % of the patients had no fever at 
the second day and 99 % were not febrile on the third day 
of medication (D2). One patient was still febrile and with 
parasitaemia on D2, being classified as ETF. By D3 the 
totality of patients was cleared of fever. During the fol-
low-up period 13 and 6 patients still had parasite positive 
blood smear on days 3 and 7 respectively, not presenting 
any clinical signs.
Treatment outcomes
Of the 103 patients, in the study, 90.3  % (n =  93) were 
classified as ACPR. Nine patients exhibited parasitaemia 
after treatment with AL. The global failure rate before 
PCR correction was 9.7 % (n = 10). One patient, under 
5 years of age, had persistent fever and parasitaemia until 
day 2, which was classified as ETF, according to WHO 
protocol, eight patients were classified as LPF, being 
six asymptomatic patients with parasite positive blood 
smear on D7 and two asymptomatic with blood parasi-
taemia on D14 and D28 respectively. One febrile patient 
presented parasites on D28 and was classified as LCF. 
After PCR correction, the overall cure rate was 91.2  % 
(n = 94); recrudescence was found in eight patients and 
reinfection in one. Among the 21 children ≤5  years of 
age included in the study, five (23.8  %) presented treat-
ment failure and three of these had anti-malarial medica-
tion under direct observed regime, at Divina Providência 
Hospital.
According to the age group, the frequency of ACPR 
was 76.2 % in patients ≤5 (n = 16/21) years and 95.1 % 
(n = 78/82) in those aged >5 years; there was no statisti-
cally significant association between treatment outcomes 
and age groups (p  =  0.334). The treatment outcome is 
shown in Table 2.
The WHO considers the proportion of patients with 
parasitaemia on day 3 of treatment as routine indicator in 
monitoring of the P. falciparum sensitivity to artemisinin 
and its derivatives, defining suspected resistance to arte-
misinin as an increase in parasite clearance time, as evi-
denced by 10 % or more cases with parasites detectable 
on day 3 of treatment with ACT. Changing of anti-malar-
ial treatment policy is recommended when the treatment 
failure rate exceeds 10 % [4, 10, 11].
In this study, 12.6  % (n  =  13) of the 103 followed 
patients had still microscopic parasites detectable on 
D3 and failure rate of 8.8 % was met. Considering WHO 
parameters, the results met in this study might suggest 
an elongated parasite clearance time [4, 11]. The failure 
rate of 8.8  % is considered higher in comparison to the 
failure of 1.2 % found in 2004 as baseline for AL efficacy 
in Angola [6, 7] and to the average failure rates of <5 % 
are often reported in the majority of studies conducted 
in Sub-Saharan African region [2–4, 36]. In the neigh-
bouring countries, average failure rates reported were: 
2.8  % from Congo, 2.4, 6.7 and 2.9  % from Democratic 
Republic of Congo, Zambia and Tanzania, respectively 
[2, 3, 37]. Failure rates >10 % were also reported as maxi-
mal failure rates among studies carried out in African 
countries such as Burkina Faso (12.5 %) in 2007, Ghana 
Table 2 Treatment outcomes for  patients treated 
with Artemether-Lumefantrine
PCR polymerase chain reaction, n number of patients, ACPR adequate clinical 
and parasitological response, ETF early treatment failure, LTF late treatment 
failure
Clinical outcome Total Age group
Initially selected 122 28 ≤ 5 years 94 > 5 years
Number of patients: n
 PCR uncorrected responses
  Withdrawn + Lost, n (%) 19 (15.6) 7 (25) 12 (12.8)
  Eligible; n (%) 103 (100) 21 (20.4) 82 (79.6)
  Global failure; n (%) 10 (9.7) 5 (23.8) 5 (6.1)
  ETF; n (%) 1 (1 %) 1 (4.8) 0
  LCF; n (%) 1 (1) 0 1 (1.2)
  LPF; n (%) 8 (7.8) 4 (19) 4 (4.9)
  ACPR; n (%) 93 (90.3) 16 (76.2) 77 (94)
 PCR corrected responses
  Eligible; n (%) 103 (100) 21 (20.4) 82 (78.6)
  Global Failure; n (%) 9 (8.7) 5 (24) 4 (5)
  ACPR; n (%) 94 (91.2) 16 (76) 78 (95)
  Recrudescence; n (%) 2 (1.9) 1 (4.8) 1 (1.2)
  Reinfection; n (%) 1 (1) 0 1 (1.2)
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(13.8 %) in 2006 and Malawi (19.5 %) [2, 38] and a rate 
of 11.6  % was reported by Plucinski et  al. in the Zaire 
province in Angola in 2013 [39]. The adjusted—PCR 
cure rate of 91.2 % met in this study is low comparing to 
the finding of the pooled analysis of data from 31 stud-
ies conducted by Venkatesan et  al, which reported AL 
overall median ACPR of 94.8 % and regional medians of 
93.8 % for East Africa, 96.2 % for West Africa and 95.2 % 
for Asia/Oceania [40, 41]. Considering that the majority 
of the referred studies were completed before 2010, more 
studies are needed to update the understanding of the 
current efficacy of AL in Africa. The cure rate (91.2  %) 
found in this study suggests that, in accordance with 
WHO parameters, AL is still effective as first-line drug 
for uncomplicated malaria treatment in Angola, but an 
regular monitoring is necessary.
Molecular analysis
Merozoite surface protein2 (pfmsp2) genotyping
pfmsp2 genotyping was performed for all samples on day 
0 and for those with microscopic positive result from 
D14 to differentiate between new infection and recrudes-
cence. The pfmsp2 genotyping was successfully assessed 
in 96 samples from (D0). Of these, 32 samples (33.3  %) 
were collected in each year, respectively 2011, 2012 and 
2013. From the pfmsp2 genotyping analysis, 72 % (n = 69) 
of the 96 samples had just one of the studied alleles (FC27 
or IC1), therefore termed as monoclonal infections and 
the IC1 family was predominant with 62.3 % (n = 43) of 
monoclonal samples.
The remaining mixed infections, with FC and IC fami-
lies, were found in 28  % (n =  27) of the analysed sam-
ples. Polyclonal infections were found in 37.5 % of cases 
(n = 36/96) on day 0. A progressive elimination of mixed 
variants post-treatment was noticed. After day 3, no 
more samples with mixed families were detected. The 
genotyping of pfmsp2 in the 3 microscopic positive sam-
ples from day 14 demonstrated that 2 had the matching 
allelic bands of day 0, indicating recrudescence. One pos-
itive sample on day 28 did not have the matching allelic 
bands of day 0, indicating reinfection. Seven of eight 
amplified samples from patients with treatment failure 
carried IC1 family alleles. The statistic tests did not evi-
dence significant association between msp2 families iden-
tified and treatment responses (P = 0.115). In this study, 
the reduced number of samples with parasites detectable 
from day 14 constitutes a limitation for relevant conclu-
sions on recrudescent and new infection rates.
Molecular markers for drug resistance
Prevalence of SNP at 86 and 1246 positions of pfmdr1 gene
Gene fragments containing the SNP 86 (N/Y) and 1246 
(D/Y) were successfully amplified on D0 in 94 and 96 
samples, respectively. For the analysis of pfmdr1 86 
SNP, out of 94 analysed samples, 28 (29.8  %) were col-
lected in 2011, 33 (35.1 %) isolates collected in 2012 and 
33 (35.1 %) in 2013. The global ranges of frequency were 
73.4  % for the wild allele (N86), 18.1  % for the mutant 
(86Y) and 8.5 % for the mixed alleles (N + Y). The ranges 
of frequencies by years for pfmdr1 N86 allele were 68 % 
(19/28) in 2011, 69.7 % (23/33) in 2012 and 82 % (27/33) 
in 2013. In the respective years, the frequencies of the 
mutant 86Y were 21, 18.2 and 15 %; and the mixed infec-
tions was found in 11, 12 and 3 % in 2011, 2012 and 2013, 
respectively.
These results show a predominance of the wild-type 
allele for the pfmdr1 86 position, there was no significant 
association between the presence of pfmdr1 86 polymor-
phism and the year o collection (p = 0.869). The pfmdr1 
D1246 was the predominant allele in the isolates for all 
time points, and one isolate only, collected in 2012, pre-
sented the mutant allele 1246Y, this isolate was obtained 
from a patient classified as ACPR and which carried a 
mixed 86 N + Y allele.
The results of this study are in agreement with those 
reported by Fançony et al. in northern Uíge province of 
Angola in 2009, where rates of 68.1, 17.4 and 14.5 % for 
N86, 86Y and 86 N + Y, respectively, were encountered 
[42]; however, differ from those met by Menegon et  al., 
in Uíge province earlier, in 2004, where 86Y was the most 
prevalent (68.2 %) [43] and those from patients assisted 
in paediatric hospital in Luanda in 2007/2008, which 
reported a 86Y frequency of 61.3 % [32].
The analysis of pooled data from 31 studies (1995–
2010) conducted by Venkatesan et  al. in 2014 reported 
rates of 37 % (N86), 44 % (86Y) and 19 % (86 N + Y) for 
Est Africa, 51 % (N86), 14 % (86Y) and 34 % (86 N + Y) 
for West Africa and 71  % (N86), 29  % (86Y9) and 0  % 
(86Y + Y) in Asia/Oceania [41].
Variations in drug exposure seem to affect the pfmdr1 
genotype profile trend. Recently, several field studies have 
suggested that AL appeared to select the N86 wild-type 
allele of pfmdr1 gene associated to reduced susceptibil-
ity to lumefantrine. Also, the predominance of this wild-
type allele can be related to the elimination of CQ and 
AQ monotherapy [44, 45]. Therefore, the results met in 
this study could be a reflection of changes occurring in 
the local parasite populations, including the progressive 
predominance of the wild-type N86 allele, associated to 
the introduction of ACT in Angola since 2006, with elim-
ination of the CQ monotherapy.
For the pfmdr1 1246 polymorphism, the wild-type 
(D1246) was present as the major allele in the isolates. 
Just one isolate collected in 2012 presented the mutant 
allele 1246Y, this isolate was from a patient classified as 
ACPR and which carried a mixed 86 N + Y alleles. The 
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results of this study are in accordance with those found in 
a majority of studies in the African region where usually 
the mutant 1246Y is not frequent [41], but differ with the 
finding in samples from Kinshasa—DRC (2008) which 
reported frequencies of 15.5 % (n = 16/103) for pfmdr1 
1286Y and 76.7 % for D1246 alleles [46, 47].
Detection of the pfmdr1 1246Y in isolates from West 
Africa (Guinea Bissau), in DRC (central Africa) an in this 
study (Angola) reveals a emergence of this genotype pre-
viously considered rare in Africa but common in South 
America. The presence of these genotypes on this area 
may due to the increased migration phenomenon and 
globalization.
Prevalence of polymorphisms at position 769 of pfatp6 
gene
SNP at 769 (S769N) position of the pfatp6 gene were 
assessed in all samples (103), none of the isolates display-
ing the 769 N mutation; it should be noted that even the 
recrudescent samples exhibited the wild-type S769 hap-
lotype. This result coincides with Menegon et al., where 
wild-type allele S769 was found in all isolates collected 
in 2004. Similar results were reported from studies con-
ducted in the Africa Region [13, 15].
Prevalence of polymorphisms on pfK13‑propeller gene
Regarding pfK13-propeller gene, all samples (n = 21) pro-
cessed by sequencing exhibited the wild type allele in all 
analysed positions, including in SNPs considered associ-
ated to artemisinin resistance (Y493H, R539T, I543T and 
C580Y). The results of this study are in agreement with 
those reported by Plucinski and by Escobar et al., where 
wild-type alleles were found at the rendered positions of 
pf k13 gene, in isolates from Angola and Mozambique 
[39, 48]. The frequencies of genetic markers associated 
with drug resistance are shown on Table 3.
pfmdr1 gene copy number
The Table 4 shows the correlation between frequencies of 
the analysed SNPs and treatment outcomes. Ninety-three 
samples were successfully analysed by real-time PCR for 
the detection of pfmdr1 copy number on D0. The results 
demonstrated that 13 isolates (14  %) showed increased 
copy number, ranging from 2 to 3 copies. The majority 
of analysed isolates had a single copy of the gene pfmdr1 
(86 %, n = 80), 12 isolates (13 %) had two copies (1.6 ≤ 2.5 
folds) and one sample (1 %) had three copies (3.44 folds). 
The proportions of samples with amplified pfmdr1 by 
year of collection were: 12.5 % (n = 4/32) in 2011, 13.8 % 
(n = 4/29) in 2012 and 15.6 (n = 5/32) in 2013.
According to AL treatment outcomes, of the 13 samples 
with pfmdr1 increased copy number, 92.3 % (n = 12/13) were 
from patients classified as ACPR. The nine patients classified 
as treatment failure exhibited a single copy of pfmdr1 when-
ever tested, whilst the patient initially classified as LCF was 
finally confirmed as a new infection had presented two cop-
ies of the gene on D0 and a single copy for D28.
An increase in the copy number of pfmdr1 gene has 
been associated with clinical failures and within vitro 
resistance to aryl-amino-alcohols, particularly meflo-
quine (MQ), quinine (QN), and halofantrine, but also 
to lumefantrine [15, 47, 49]; the results of this study 
didn’t show a statistically significant association between 
increase in copy number of the gene pfmdr1 and thera-
peutic response to Coartem®. However, the frequency 
of isolates with increase copy number of pfmdr1 gene 
found in this study seems higher in comparison to aver-
age reported in various studies from African region [41].
According to other studies the pfmdr1 copy amplifica-
tion has been rarely found in the African region [41, 50]. 
There is no data published about pfmdr1 copy number 
from Angolan patients; however from other countries, 
and from a total of 131 isolates collected in 2005–2009 
from West Africa (n = 99) and Central Africa (n = 32), 
only 4 had pfmdr1 copy number amplification. Menard 
et al. in Cameron in 2009 did not identify samples with 
pfmdr1 gene amplification, and similar results were 
reported by Vaughan-Williams et  al. in Kwazulo Natal, 
South Africa, in 2012 [50, 51].
Conclusions
Relatively to Coartem® treatment response, the failure 
rate of 8.8  % is higher in comparison to that of 1.2  % 
found in the 2004 study for AL efficacy in Angola [2, 39], 
and the median failure rates of <5 % often reported in the 
majority of studies conducted in sub-Saharan African 
region; however, the cure rate (91.2 %) of this study sug-
gests that AL is still effective as first line drug for uncom-
plicated malaria treatment in Angola, in accordance to 
the WHO parameters [4, 21].
The predominance of the wild-type allele for the pfmdr1 
86 and 1246 positions found in this study is in agreement 
with those reported in various studies conducted in the 
African region [41]. Recently, several field studies have 
suggested that AL eliminates the mutated parasite popu-
lation allowing the wild-type to become predominant. 
Considering that ACT was introduced in Angola from 
2006, and after 7  years of AL regime implementation, 
the results met in this study could reflect changes occur-
ring in the local parasite populations, including progres-
sive elimination of mutant 86Y allele previously selected 
by CQ. Detection of the pfmdr1 1246Y in this study as 
well as in others studies of isolates from West Africa 
(Guinea Bissau) and DRC (Central Africa) seems to indi-
cate a emergence of this genotype previously considered 
rare in Africa, may be due to globalization and migration. 
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Table 3 Prevalence of genetic markers associated with drug resistance
pfmdr1, Plasmodium falciparum multidrug resistance 1 gene, SNP, Single nucleotide polymorphism, Pfatp6, Plasmodium falciparum sarco/endoplasmic reticulum 
calcium-ATPase6 gene, K13, mutations in the PF3D7_1343700 kelch propeller domain (‘K13-propeller’); wt, wild type allele, mixed, mix infections, >copy, 
pfmdr1amplifyed (with >1 copy)
Year Gene SNP’s n Allele %
Wild‑type Mutant Mixed allele
2011 pfmdr1 N86Y 28 68 % (n = 19) 21 % (n = 6) 11 % (n = 3)
D1246Y 31 100 % 0 0
>copy 4/32 (12.5 %)
pfatp6 S769N 37 100 % 0 0
K13 Y493H 5 100 % 0 0
R539T 5 100 % 0 0
I543T 5 100 % 0 0
C580Y 5 100 % 0 0
2012 pfmdr1 N86Y 33 69.7 % (n = 23) 18.2 % (n = 6) 12.1 % (n = 4)
D1246Y 32 97 % (n = 3) 3 % (n = 1) 0
>copy 4/29 (13.8 %)
pfatp6 S769 N 33 100 % 0 0
K13 Y493H 7 100 % 0 0
R539T 7 100 % 0 0
I543T 7 100 % 0 0
C580Y 7 100 % 0 0
2013 pfmdr1 N86Y 33 82 % (n = 27) 15 % (n = 5) 3 % (n = 1)
D1246Y 33 100 % 0 0
>copy 5/32 (15.6 %)
pfatp6 S769 N 33 100 % 0 0
K13 Y493H 9 100 % 0 0
R539T 9 100 % 0 0
I543T 9 100 % 0 0
C580Y 9 100 % 0 0
Total pfmdr1 N86Y 94 73.4 (n = 69) 18.1 % (n = 17) 8.5 % (n = 8)
D1246Y 96 99 (n = 86) 1 (n = 1) 0
>copy 13/93 (14 %)
pfatp6 S769N 103 100 % (n = 103) 0 0
K13 Y493H 21 100 % 0 0
R539T 21 100 % 0 0
I543T 21 100 % 0 0
C580Y 21 100 % 0 0
Table 4 Correlation between SNP frequencies and treatment outcomes
pfmdr1, Plasmodium falciparum multidrug resistance 1 gene, SNP, Single nucleotide polymorphism, Pfatp6, Plasmodium falciparum sarco/endoplasmic reticulum 
calcium-ATPase6 gene, K13, mutations in the PF3D7_1343700 kelch propeller domain (‘K13-propeller’); wt, wild type allele; mixed, mix infections, >copy, pfmdr1 





pfmdr1 86 pfmdr1 1246 Pfatp6 769 pfK13
N86 86Y 86 N + Y D1246 1246Y S769 769 N wt mutant












0 100 % 
(n = 12)
0 13 % 
(n = 12/92)




11.1 %  
(n = 1)
100 (n = 7) 0 100 % 
(n = 10)
0 100 % 
(n = 9)
0 11 % 
(n = 1/9)
Total (n) 69 17 8 95 1 103 0 21 0 13
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The frequency of isolates with increase copy number of 
pfmdr1 gene found in this study seems higher in com-
parison to others reported in various studies from the 
African region where copy amplification of this gene has 
been rarely found. The analysis of the clinical outcomes 
after treatment with Coartem® did not link a particular 
genotype with treatment failure met in this study.
Globally, the result of this study suggests a change 
of the profile of the parasite population circulating in 
Angola, reflected by a decreased susceptibility to AL and 
a relative alteration in pfmdr1 genotyping in comparison 
to many studies previously realized in the area. How-
ever, the low number of patients in the study and with 
treatment failure could be a limitation for a consistent 
conclusion.
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